Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats

Wang,Hongwu; Qiu,Xiaoyan; Ni,Ping; Qiu,Xuerong; Lin,Xiaobo; Wu,Weizhao; Xie,Lichun; Lin,Limin; Min,Juan; Lai,Xiulan; Chen,Yunbin; Ho,Guyu; Ma,Lian

doi:10.3892/ijmm.2013.1572

Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats

Authors:
- Hongwu Wang
- Xiaoyan Qiu
- Ping Ni
- Xuerong Qiu
- Xiaobo Lin
- Weizhao Wu
- Lichun Xie
- Limin Lin
- Juan Min
- Xiulan Lai
- Yunbin Chen
- Guyu Ho
- Lian Ma
View Affiliations

Affiliations: Department of Pediatrics, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China, Department of Obstetrics and Gynecology, Shenzhen Pingshan Women's And Children's Hospital, Shenzhen, Guangdong 518118, P.R. China, Transformation Medical Center, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China
Published online on: November 28, 2013 https://doi.org/10.3892/ijmm.2013.1572
Pages: 263-270
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Islet transplantation involves the transplantation of pancreatic islets from the pancreas of a donor to another individual. It has proven to be an effective method for the treatment of type 1 diabetes. However, islet transplantation is hampered by immune rejection, as well as the shortage of donor islets. Human umbilical cord Wharton's jelly-derived mesenchymal stem cells (HUMSCs) are an ideal cell source for use in transplantation due to their biological characteristics and their use does not provoke any ethical issues. In this study, we investigated the immunological characteristics of HUMSCs and their effects on lymphocyte proliferation and the secretion of interferon (IFN)-γ, and explored whether direct cell-to-cell interactions and soluble factors, such as IFN-γ were important for balancing HUMSC-mediated immune regulation. We transplanted HUMSCs into diabetic rats to investigate whether these cells can colonize in vivo and differentiate into pancreatic β-cells, and whether the hyperglycemia of diabetic rats can be improved by transplantation. Our results revealed that HUMSCs did not stimulate the proliferation of lymphocytes and did not induce allogeneic or xenogeneic immune cell responses. qRT-PCR demonstrated that the HUMSCs produced an immunosuppressive isoform of human leukocyte antigen (HLA-I) and did not express HLA-DR. Flow cytometry revealed that the HUMSCs did not express immune response-related surface antigens such as, CD40, CD40L, CD80 and CD86. IFN-γ secretion by human peripheral blood lymphocytes was reduced when the cells were co-cultured with HUMSCs. These results suggest that HUMSCs are tolerated by the host in an allogeneic transplant. We transplanted HUMSCs into diabetic rats, and the cells survived in the liver and pancreas. Hyperglycemia of the diabetic rats was improved and the destruction of pancreatic cells was partly repaired by HUMSC transplantation. Hyperglycemic improvement may be related to the immunomodulatory effects of HUMSCs. However, the exact mechanisms involved remain to be further clarified.

View Figures

View References

1	Atkinson MA and Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 358:221–229. 2001. View Article : Google Scholar : PubMed/NCBI
2	Noguchi H: Pancreatic islet transplantation. World J Gastrointest Surg. 1:16–20. 2009. View Article : Google Scholar
3	Matsumoto S: Islet cell transplantation for Type 1 diabetes. J Diabetes. 2:16–22. 2010. View Article : Google Scholar
4	Shapiro AM, Lakey JR, Ryan EA, et al: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunostippressive regimen. N Engl J Med. 343:230–238. 2000. View Article : Google Scholar
5	Wang HW, Lin LM, He HY, et al: Human umbilical cord mesenchymal stem cells derived from Wharton’s jelly differentiate into insulin-producing cells in vitro. Chin Med J. 124:1534–1539. 2011.
6	Jiang J, Au M, Lu K, et al: Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells. 25:1940–1953. 2007. View Article : Google Scholar : PubMed/NCBI
7	Karnieli O, Izhar-Prato Y, Bulvik S, et al: Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells. 25:2837–2844. 2007. View Article : Google Scholar : PubMed/NCBI
8	Mueller SM and Glowacki J: Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem. 82:583–590. 2001. View Article : Google Scholar : PubMed/NCBI
9	Stenderup K, Justesen J, Clausen C and Kassem M: Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 33:919–926. 2003. View Article : Google Scholar : PubMed/NCBI
10	Xie QP, Huang H, Xu B, et al: Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation. 7:483–91. 2009.PubMed/NCBI
11	Shi Y: Generation of functional insulin-producing cells from human embryonic stem cells in vitro. Methods Mol Biol. 636:79–85. 2010. View Article : Google Scholar : PubMed/NCBI
12	Le Blanc K, Tammik L, Sundberg B, et al: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 57:11–20. 2003.
13	Krampera M, Glennie S, Dyson J, et al: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 101:3722–3729. 2003. View Article : Google Scholar : PubMed/NCBI
14	Meisel R, Zibert A, Laryea M, et al: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 103:4619–4621. 2004. View Article : Google Scholar : PubMed/NCBI
15	Alhadlaq A and Mao JJ: Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 13:436–438. 2004. View Article : Google Scholar : PubMed/NCBI
16	Le Blanc K and Pittenger M: Mesenchymal stem cells: progress toward promise. Cytotherapy. 7:36–45. 2005.PubMed/NCBI
17	Beyer Nardi N and da Silva Meirelles L: Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 174:249–282. 2006.
18	Wang HS, Hung SC, Peng ST, et al: Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 22:1330–1337. 2004.
19	Ma L, Feng XY, Cui BL, et al: Human umbilical cord Wharton’s Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J. 118:1987–1993. 2005.
20	Qian Q, Qian H, Zhang X, et al: 5-Azacytidine induces cardiac differentiation of human umbilical cord-derived mesenchymal stem cells by activating extracellular regulated kinase. Stem Cells Dev. 21:67–75. 2012. View Article : Google Scholar
21	He D, Wang J, Gao Y and Zhang Y: Differentiation of PDX1 gene-modified human umbilical cord mesenchymal stem cells into insulin-producing cells in vitro. Int J Mol Med. 28:1019–1024. 2011.PubMed/NCBI
22	Huang P, Lin LM, Wu XY, et al: Differentiation of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells into germ-like cells in vitro. J Cell Biochem. 109:747–754. 2010.
23	Ghio M, Contini P, Negrini S, et al: Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol. 39:3459–3468. 2009. View Article : Google Scholar : PubMed/NCBI
24	Stumpf AN, van der Meijden ED, van Bergen CA, et al: Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood. 114:3684–3692. 2009. View Article : Google Scholar : PubMed/NCBI
25	Antin JH: Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 347:36–42. 2002. View Article : Google Scholar : PubMed/NCBI
26	Leitner J, Kuschei W, Grabmeier-Pfistershammer K, et al: T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J Immunol Methods. 362:131–141. 2010. View Article : Google Scholar : PubMed/NCBI
27	Shi M, Liu ZW and Wang FS: Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol. 164:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
28	Sioud M: New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol. 73:79–84. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yagi H, Soto-Gutierrez A, Parekkadan B, et al: Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 19:667–679. 2010. View Article : Google Scholar : PubMed/NCBI
30	Aggarwal S and Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105:1815–1822. 2005. View Article : Google Scholar : PubMed/NCBI
31	Yano S, Kuroda S, Shichinohe H, et al: Bone marrow stromal cell transplantation preserves gamma aminobutyric acid receptor function in the injured spinal cord. J Neurotrauma. 23:1682–1692. 2006. View Article : Google Scholar : PubMed/NCBI